Utilization of iron dextran.
The utilization of iron dextran was investigated in normal subjects, in patients with iron-deficiency anaemia, and in anaemias associated with rheumatoid arthritis, reticulosis, and uraemia. Utilization of iron for haemoglobin formation at 14 days was found to be depressed in patients with rheumatoid arthritis, reticulosis, and uraemia, but when a concomitant iron-deficiency anaemia was present utilization was significantly increased. When iron dextran is used to treat anaemias in such conditions an optimum therapeutic response will be obtained only when bone marrow iron stores are absent.
D000740:Anemia / Q000378:metabolism; D000747:Anemia, Hypochromic / Q000378:metabolism*; D001172:Arthritis, Rheumatoid / Q000378:metabolism; D001853:Bone Marrow / Q000378:metabolism; D006454:Hemoglobins / Q000096:biosynthesis; D006689:Hodgkin Disease / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism; D007503:Iron Isotopes; D007505:Iron-Dextran Complex / Q000097:blood / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism; D008297:Male; D014511:Uremia / Q000378:metabolism
D006454:Hemoglobins; D007503:Iron Isotopes; D007505:Iron-Dextran Complex; D007501:Iron